FREQUENCY OF MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH DE NOVO CORONARY ARTERY DISEASE REVASCULARIZED WITH EVEROLIMUS-ELUTING STENTS

Abstract

Objective: The aim of this study was to determine the frequency of major adversecardiac events in patients with de novo coronary artery disease revascularizedwith everolimus-eluting stents.

Methodology: This prospective cross sectional study was carried out in thedepartment of cardiology, Lady Reading Hospital Peshawar from October 2011to November 2012. Patients with de novo coronary artery disease, who wererevascularized with everolimus-eluting stents, were included in the study. Theirbaseline clinical and procedural characteristics were recorded from hospitalrecord. Data regarding MACE defined as composite of myocardial infarction,stent thrombosis, recurrence of ischemia and death were obtained on follow up.

Result: A total of 420 patients were included in the study in which 320(76.2%)were male. Risk factors for coronary artery disease were; diabetes mellitus147(35%), hypertension 256(61%), hypercholesterolemia 147(35%) andsmoking 100(23.8%). Most of patients had stable angina 285(67.9%). Oncoronary angiography, 98(23.3%) of patients had single vessel disease,152(36.2%) had two vessel disease and 170(40.5%) had three vessel disease.Left anterior descending artery was most frequently affected vessel 242(57.6%).Mean lesion length was 25±8.1 mm. Mean stent length/lesion was 26.03±7.09mmwhile mean stent diameter/lesion was 3.14±0.29mm. Tirofiben (Agrastate)was used in 19(4.5%) of patients.On follow up, MACE occurred in 16(3.8%) patients, 6(1.4%) patients developedmyocardial infarction, 5(1.2%) developed recurrence of ischemia, 6(1.4%) ofpatients developed stent thrombosis and 6(1.4%) of patients died during studyperiod.

Conclusion: Everolimus-eluting stents carries a lower risk of major adversecardiac events in patients with de novo coronary disease.